These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 9129859)

  • 1. Use of Irwin's restricted mean as an index for comparing survival in different treatment groups--interpretation and power considerations.
    Karrison TG
    Control Clin Trials; 1997 Apr; 18(2):151-67. PubMed ID: 9129859
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Restricted mean survival time: Does covariate adjustment improve precision in randomized clinical trials?
    Karrison T; Kocherginsky M
    Clin Trials; 2018 Apr; 15(2):178-188. PubMed ID: 29502444
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A flexible and coherent test/estimation procedure based on restricted mean survival times for censored time-to-event data in randomized clinical trials.
    Horiguchi M; Cronin AM; Takeuchi M; Uno H
    Stat Med; 2018 Jul; 37(15):2307-2320. PubMed ID: 29682762
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of survival distributions in clinical trials: A practical guidance.
    Chen X; Wang X; Chen K; Zheng Y; Chappell RJ; Dey J
    Clin Trials; 2020 Oct; 17(5):507-521. PubMed ID: 32594788
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nonparametric analysis of covariance for hypothesis testing with logrank and Wilcoxon scores and survival-rate estimation in a randomized clinical trial.
    Tangen CM; Koch GG
    J Biopharm Stat; 1999 May; 9(2):307-38. PubMed ID: 10379696
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Survival trial design and monitoring using historical controls.
    Wu J; Xiong X
    Pharm Stat; 2016 Sep; 15(5):405-11. PubMed ID: 27307025
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bayesian variable selection method for censored survival data.
    Faraggi D; Simon R
    Biometrics; 1998 Dec; 54(4):1475-85. PubMed ID: 9883546
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Survival model predictive accuracy and ROC curves.
    Heagerty PJ; Zheng Y
    Biometrics; 2005 Mar; 61(1):92-105. PubMed ID: 15737082
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Improved precision in the analysis of randomized trials with survival outcomes, without assuming proportional hazards.
    Díaz I; Colantuoni E; Hanley DF; Rosenblum M
    Lifetime Data Anal; 2019 Jul; 25(3):439-468. PubMed ID: 29492746
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Designing clinical trials with (restricted) mean survival time endpoint: Practical considerations.
    Eaton A; Therneau T; Le-Rademacher J
    Clin Trials; 2020 Jun; 17(3):285-294. PubMed ID: 32063031
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Restricted mean survival time: an alternative to the hazard ratio for the design and analysis of randomized trials with a time-to-event outcome.
    Royston P; Parmar MK
    BMC Med Res Methodol; 2013 Dec; 13():152. PubMed ID: 24314264
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The type I error and power of non-parametric logrank and Wilcoxon tests with adjustment for covariates--a simulation study.
    Jiang H; Symanowski J; Paul S; Qu Y; Zagar A; Hong S
    Stat Med; 2008 Dec; 27(28):5850-60. PubMed ID: 18759373
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Augmenting the logrank test in the design of clinical trials in which non-proportional hazards of the treatment effect may be anticipated.
    Royston P; Parmar MK
    BMC Med Res Methodol; 2016 Feb; 16():16. PubMed ID: 26869168
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sample size calculation for the augmented logrank test in randomized clinical trials.
    Hattori S; Komukai S; Friede T
    Stat Med; 2022 Jun; 41(14):2627-2644. PubMed ID: 35319100
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sample size determination for comparing several survival curves with unequal allocations.
    Halabi S; Singh B
    Stat Med; 2004 Jun; 23(11):1793-815. PubMed ID: 15160409
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A simulation study comparing the power of nine tests of the treatment effect in randomized controlled trials with a time-to-event outcome.
    Royston P; B Parmar MK
    Trials; 2020 Apr; 21(1):315. PubMed ID: 32252820
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An approach to trial design and analysis in the era of non-proportional hazards of the treatment effect.
    Royston P; Parmar MK
    Trials; 2014 Aug; 15():314. PubMed ID: 25098243
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adaptive trial design: a general methodology for censored time to event data.
    Jahn-Eimermacher A; Ingel K
    Contemp Clin Trials; 2009 Mar; 30(2):171-7. PubMed ID: 19130902
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Log-Rank Test vs MaxCombo and Difference in Restricted Mean Survival Time Tests for Comparing Survival Under Nonproportional Hazards in Immuno-oncology Trials: A Systematic Review and Meta-analysis.
    Mukhopadhyay P; Ye J; Anderson KM; Roychoudhury S; Rubin EH; Halabi S; Chappell RJ
    JAMA Oncol; 2022 Sep; 8(9):1294-1300. PubMed ID: 35862037
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A clinical trial design using the concept of proportional time using the generalized gamma ratio distribution.
    Phadnis MA; Wetmore JB; Mayo MS
    Stat Med; 2017 Nov; 36(26):4121-4140. PubMed ID: 28815655
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.